Page last updated: 2024-08-22

lutetium and Myelodysplastic Syndromes

lutetium has been researched along with Myelodysplastic Syndromes in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Baum, RP; Bodei, L; Cremonesi, M; Drozdov, I; Grana, CM; Kidd, M; Krenning, EP; Kwekkeboom, DJ; Lepensky, C; Modlin, IM; Paganelli, G1
Kesavan, M; Turner, JH1

Reviews

1 review(s) available for lutetium and Myelodysplastic Syndromes

ArticleYear
Myelotoxicity of Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Decade of Experience.
    Cancer biotherapy & radiopharmaceuticals, 2016, Volume: 31, Issue:6

    Topics: Capecitabine; Dacarbazine; Female; Humans; Lutetium; Male; Middle Aged; Myelodysplastic Syndromes; Neuroendocrine Tumors; Octreotide; Radiation Injuries; Radioisotopes; Radiopharmaceuticals; Temozolomide

2016

Trials

1 trial(s) available for lutetium and Myelodysplastic Syndromes

ArticleYear
Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors.
    European journal of nuclear medicine and molecular imaging, 2015, Volume: 42, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Female; Humans; Leukemia, Myeloid, Acute; Lutetium; Male; Middle Aged; Myelodysplastic Syndromes; Neuroendocrine Tumors; Octreotide; Radiation Dosage; Radiopharmaceuticals; Receptors, Peptide; Yttrium Radioisotopes

2015